This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Forbess, J. M. Articles by Jonas, R. A. Search for Related Content PubMed Articles by Forbess, J. M. Articles by Jonas, R. A.

(Circulation. 1995;92:262-266.)
© 1995 American Heart Association, Inc.

Articles

Ten-Year Institutional Experience With Palliative Surgery for Hypoplastic Left Heart Syndrome

Risk Factors Related to Stage I Mortality

Joseph M. Forbess, MD; Nancy Cook, SCD; Stephen J. Roth, MD; Alain Serraf, MD; John E. Mayer, Jr, MD; Richard A. Jonas, MD

From the Departments of Cardiovascular Surgery (J.M.F., N.C., A.S., J.E.M., R.A.J.) and Cardiology (S.J.R.), Children's Hospital of Boston, and the Departments of Surgery and Pediatrics, Harvard Medical School, Boston, Mass.

Correspondence to Richard A. Jonas, MD, Department of Cardiovascular Surgery, Children's Hospital, 300 Longwood Ave, Boston, MA 02115.

	Abstract

Top Abstract Introduction Methods Anatomic Findings Results Discussion References

 
Background We reviewed 212 consecutive patients who underwent stage I palliative surgery for hypoplastic left heart syndrome (HLHS) at our institution between January 1983 and June 1993.

Methods and Results Six surgeons participated in the care of these patients. Follow-up is 97% complete. Preoperative anatomic and physiological factors and procedural features of the stage I operation were analyzed for impact on stage I mortality, survival to stage II palliation, and actuarial survival. Hospital mortality was not significantly lower during the second half of the study period (P=.242). Operative mortality was 46.2%. Multivariate analysis revealed improved stage I operative survival in patients with mitral stenosis (MS) and aortic stenosis (AS; P=.006). Additional risk factors for stage I mortality were a lower immediately pre–stage I pH (P=.034) and weight <3 kg (P=.015). Overall first-year actuarial survival for MS/AS was 59%, and it was 33% for all others (P=.001). Among stage I survivors, patients with MS/AS were more likely to survive to stage II palliation (P=.031). Analysis of actuarial survival of stage I survivors showed that a smaller ascending aorta (P<.001), aortic atresia (P<.001), and mitral atresia (P=.002) were all risk factors for intermediate death.

Conclusions Preoperative anatomic and physiological state are predictors of stage I mortality. HLHS anatomic subtype also influences intermediate outcome, most notably pre–stage II attrition. These data may be useful in choosing initial management for patients with HLHS.

Key Words: surgery • mortality • hypoplastic left heart syndrome • survival

	Introduction

Top Abstract Introduction Methods Anatomic Findings Results Discussion References

 
Hypoplastic left heart syndrome is one of the more common congenital heart defects and is the most common anomaly resulting in death from congenital heart disease during the first year of life in the United States.¹ The 1980s witnessed the simultaneous development and implementation of two surgical approaches to the neonate with HLHS. Norwood et al^{2 3 4} reported the first successful application of staged reconstructive surgery and have subsequently reported sizable series of patients undergoing such a sequence of surgical therapy. Bailey et al,^{5 6 7} in contrast, have introduced and espoused transplantation in the neonatal period for HLHS. Both of these treatment options have their particular difficulties and limitations. Neonatal cardiac allotransplantation is acutely limited by the supply of suitable donor hearts.⁸ The reconstructive approach requires a sequence of technically demanding procedures that may be fraught with high operative mortality and significant interstage attrition.^{9 10} A previous analysis of one surgeon's experience with staged reconstruction at this institution suggested that some HLHS subgroups are at higher risk for mortality and attrition.¹¹ Norwood and others have been unable to identify high-risk subgroups.^{3 12} To address this apparent discrepancy and to identify any additional patient- or procedure-specific risk factors related to first-stage palliation of HLHS, we reviewed all patients who underwent stage I palliation for HLHS at Boston Children's Hospital between January 1983 and June 1993. Specifically, we examined stage I mortality, survival to second-stage palliation, and actuarial survival among patients who survived stage I palliation.

	Methods

Top Abstract Introduction Methods Anatomic Findings Results Discussion References

 
A total of 212 patients underwent stage I palliation for HLHS at Children's Hospital, Boston, between January 1983 and June 1993. Patient data were compiled by review of clinical records, including operative reports, and preoperative imaging studies. The diagnosis of HLHS was based on angiographic or two-dimensional echocardiographic evidence of a diminutive ascending aorta, aortic atresia or stenosis, and a hypoplastic left ventricle. It is not our current practice to perform angiography if preoperative transcatheter interventions are not necessary. Of the 212 patients, 153 (72%) were boys and 59 (28%) were girls. Age at operation ranged from 1 to 38 days, with a median of 4 days. Weight at operation ranged from 1.9 to 5.0 kg, with a median of 3.4 kg.

Operative survival was defined as survival of >30 days and the ability to leave the hospital. Follow-up information was obtained from 111 (97%) of the 114 survivors. Follow-up was obtained directly from the patient's family or primary cardiologist during a 1-month period ending April 1, 1994. Time to follow-up (or late death) ranged from 0.1 to 9.7 years, with a median of 1.7 years. This constituted a total of 267 patient-years. Intermediate results were evaluated by the incidence of death, survival to second-stage palliation, and actuarial survival estimates. Potential risk factors for early mortality were analyzed in contingency tables with ² or Fisher's exact tests. Multivariate analyses of operative mortality, mortality before stage II palliation, and overall intermediate mortality among stage I survivors were performed using stepwise logistic regression and Cox regression models. The relation of discrete variables to survival among stage I survivors was examined with the log-rank test. Survivorship estimates were made by the Kaplan-Meier method. All analyses used a standard, commercially available software package (SAS Institute, Inc).

	Anatomic Findings

Top Abstract Introduction Methods Anatomic Findings Results Discussion References

 
Fig 1 shows the distribution of anatomic subtypes in the study population. Of the 212 patients, 88 (41.5%) had MA with AA, 59 (27.8%) had MS with AA, 51 (24.1%) had MS with AS, and 14 (6.6%) had other variants.

View larger version (18K): [in this window] [in a new window]   Figure 1. Pie chart showing distribution of hypoplastic left heart syndrome anatomic subtypes in study population.

Fig 2 displays the distribution of ascending aorta diameters in the study population. The ascending aorta diameters in 116 patients (57%) were between 2 and 4 mm; in 18 patients (8.8%), <2 mm; and in 71 (35%), >4 mm. Ascending aorta diameter tended to be greater in those patients with AS than in those with AA (Fig 3).

View larger version (13K): [in this window] [in a new window]   Figure 2. Bar graph showing distribution of ascending aorta diameter for all 205 patients in whom this information was available.

View larger version (17K): [in this window] [in a new window]   Figure 3. Bar graph showing distribution of ascending aorta diameter for patients with aortic atresia vs aortic stenosis.

The presence of a discrete coarctation of the aorta was noted preoperatively in 103 patients (49%). Pre–stage I right ventricular function was identified as normally preserved in 127 patients (60%), mildly depressed in 40 (19%), moderately depressed in 31 (15%), and severely depressed in 11 (5%). Tricuspid regurgitation was noted to be moderate in 14 patients (7%) and severe in 2 (1%). Forty-six (22%) were noted to have restrictive atrial septal defects.

Operative Features
Various techniques were used in the first-stage reconstructions performed during the study period. All but 2 stage I procedures were performed with cardiopulmonary bypass and hypothermic circulatory arrest. The mean duration of circulatory arrest was 62 minutes (SD, 9.9 minutes). Sixteen patients required a second period of circulatory arrest averaging 24 minutes (SD, 5.9 minutes). Pulmonary arterial to aortic continuity was established in several ways. To facilitate statistical analyses, these were classified as type 1: direct anastomosis of the divided proximal pulmonary artery to the side of the ascending aorta with augmentation of the neoaortic arch with homograft, autologous pericardium, or synthetic gusset (n=105); type 2: anastomosis of the proximal main pulmonary artery to the underside of the aortic arch in an end-to-side fashion directly or with a homograft, synthetic, or autologous pericardium interposition tube graft (n=92); and type 3: other forms of palliative reconstruction (n=15). The types of operation with materials used for neoaortic reconstruction are shown in Table 1. A variety of systemic-to-pulmonary shunts were also used during the study period. One hundred eighteen patients (56%) received 4-mm RMBTSs, 74 (35%) had 3.5-mm RMBTSs, and 11 (5.2%) had central shunts placed. The current reconstruction of choice at our institution is a type 1 procedure with a 3.5-mm RMBTS. An additional technique applied to this population is that of delayed sternal closure. The chest was left open in 72 patients (34%), and 51 underwent delayed sternal closure at a mean of 3.8 days (SD, 2.4 days).

View this table: [in this window] [in a new window]   Table 1. Technical Aspects of Stage I Palliation

	Results

Top Abstract Introduction Methods Anatomic Findings Results Discussion References

 
Table 2 summarizes the duration of postoperative intensive care unit and hospital stay. The median intensive care unit stay for operative survivors was 11 days, with a range of 4 to 105 days. The median duration of postoperative mechanical ventilation was 6 days in operative survivors, with a range of 2 to 81 days. The median hospital stay among operative survivors was 33.1 days, with a range of 9 to 341 days. The median hospital stay among all patients was 23.5 days, with a range of 0 to 341 days.

View this table: [in this window] [in a new window]   Table 2. Postoperative Hospitalization Summary After Neonatal Palliative Surgery

There were 98 operative deaths (46.2%). Fig 4 shows hospital mortality by anatomic subtype. The results of univariate analysis of possible risk factors for stage I hospital mortality are shown in Table 3. Patients with ascending aorta diameter <2 mm were at increased risk for operative mortality (P=.002). These patients were more likely to receive a type 2 stage I procedure. Only 7 of the 19 patients (37%) with ascending aorta diameters <2 mm underwent type 1 operations, whereas 95 of the remaining 186 patients (51%) underwent a type 1 operation.

View larger version (34K): [in this window] [in a new window]   Figure 4. Bar graph showing hospital mortality according to anatomic subtype.

View this table: [in this window] [in a new window]   Table 3. Univariate Risk Factor Analysis: Hospital Mortality

Patients weighing <3 kg were at higher risk for hospital death (P=.024), whereas patients with an immediately preoperative pH >7.5 were more likely to survive (P=.017). There was a trend toward improved survival in those patients with MS/AS by univariate analysis (P=.06). Preoperative right ventricular or tricuspid valve function, type of stage I procedure, type of systemic-to-pulmonary shunt, operative surgeon, or year of operation did not influence operative mortality (P>.05). Independent risk factors for stage I mortality identified in multivariate analysis were weight <3 kg (P=.015) and lower immediately preoperative pH (P=.0361). MS/AS patients were at dramatically lower risk for stage I death (P=.006).

Survival to stage II palliation was also analyzed as an end point. Table 4 summarizes the findings of univariate analysis. Patients who underwent stage I later in the study period (P<.001) and those with MS/AS (P=.001) were much more likely to survive to stage II surgery. Those who had ascending aorta diameter <2.5 mm (P=.018) and those in whom synthetic tube grafts were used in neoaortic reconstruction (P=.03) were less likely to survive to a second-stage operation. Patients receiving a 3.5-mm RMBTS (P=.025) and those undergoing delayed sternal closure (P=.024) were more likely to survive to a stage II procedure. There was a trend toward increased survival to stage II in patients who underwent a type 1 reconstruction (direct side-to-side anastomosis of main pulmonary artery to ascending aorta with aortic arch augmentation, P=.059). Multivariate analysis also revealed that MS/AS patients were less likely to die (P=.031) and patients with synthetic tube graft neoaortic reconstruction were more likely to die (P=.033) before stage II.

View this table: [in this window] [in a new window]   Table 4. Univariate Risk Factor Analysis: Survival to Stage II Palliation

Actuarial survival of all patients by anatomic subtype is shown in Fig 5. Overall 1-year actuarial survival was 59% in MS/AS patients and 33% for all others (P=.001). Actuarial survival among stage I survivors, similarly classified according to anatomic subtype, is shown in Fig 6. Again, MS/AS patients showed increased intermediate survival (P=.001), as did those with ascending aorta diameters >4.5 mm (P=.005). In contrast, patients with either mitral atresia (P=.002) or aortic atresia (P=.001) had lower survival. Patients who underwent a type 1 stage I reconstruction had improved actuarial survival (P=.004) compared with those who underwent other types of stage I reconstruction. Multivariate analysis with the proportional-hazards model showed that aortic atresia was the only independent risk factor for death among operative survivors (P<.001).

View larger version (14K): [in this window] [in a new window]   Figure 5. Graph showing actuarial survival for all patients classified by anatomic subtype. Error bars indicate 70% CIs.

View larger version (14K): [in this window] [in a new window]   Figure 6. Graph showing actuarial survival for stage I operative survivors classified by anatomic subtype. Error bars indicate 70% CIs.

	Discussion

Top Abstract Introduction Methods Anatomic Findings Results Discussion References

 
Although a number of institutions have dedicated considerable effort toward programs of staged reconstruction for HLHS for more than a decade, controversy over the influence of anatomic subtype on stage I survival persists. A smaller, single-surgeon series from this institution previously suggested the importance of anatomic subtype in outcome after stage I palliation.¹¹ There was a trend for patients with MS/AA to be at higher risk for stage I mortality in that series.¹¹ Norwood and Bove and their colleagues have not observed such an influence in several reports of their respective HLHS experiences.^{3 4 12 13} In the consecutive 10-year institutional experience of this report, pre–stage I anatomy strongly influenced both operative and intermediate mortality among stage I survivors. Patients with MS/AS, who tended to have larger ascending aorta diameter, had improved operative survival, survival to stage II palliation, and overall intermediate survival. During the early years of the study period, these patients were more likely to undergo a type 1 reconstruction. Patients with particularly diminutive ascending aortas were more likely to undergo a type 2 repair. We have speculated that the dependence of the coronary arteries on retrograde perfusion through an attenuated length of ascending aorta has contributed to the apparently inferior early and intermediate results in these patients. As a result, it is now our practice to perform a type 1 repair in virtually all patients. If a type 2 repair is nevertheless chosen, we commonly divide the ascending aorta and reimplant it end to side above the neoaortic annulus in an effort to improve coronary perfusion.

A lower immediately preoperative pH, perhaps reflecting the inadequacy of resuscitative efforts, was also a predictor of higher stage I mortality. This confirms the observation previously made at this institution¹¹ and suggests a beneficial role for prenatal diagnosis, by which acidosis may be largely avoided.

The intermediate results of the MS/AS patients in this series are comparable to those obtained with transplantation when one takes into account the mortality associated with the pretransplant waiting period. The most prolific HLHS transplant center has reported an overall 5-year actuarial survival of 61%.⁷ However, the early mortality for the majority of the patients in the study population, with atresia of one or both of the left heart valves, did not decrease significantly during the study period. This finding contrasts sharply with the results of reparative neonatal cardiac surgery at our institution.¹⁴ There was, however, an encouraging increase in survival to stage II palliation among all patients later in the study period. Of all stage I survivors in the past 5 years, 85% have undergone a second-stage palliative procedure. The vast majority of these second-stage procedures are a bidirectional cavopulmonary connection. The second-stage bidirectional cavopulmonary connection has improved survival at completion of the Fontan procedure at this institution and is the subject of a subsequent report (unpublished data).

We conclude from these data that HLHS patients with MS/AS may undergo a course of reconstructive palliative surgery with overall results similar to those currently offered by cardiac transplantation.⁷ Patients with other anatomic subtypes face significant early mortality but are now more likely to survive to subsequent palliative procedures. Given the short supply of organ donors, the most appropriate HLHS patients for transplantation are those with either mitral or aortic valve atresia, particularly those who weigh <3 kg and/or have an ascending aorta diameter of <2 mm. Prospective trials are necessary to confirm such speculation.

	Selected Abbreviations and Acronyms

 

AA = aortic atresia AS = aortic stenosis HLHS = hypoplastic left heart syndrome MA = mitral atresia MS = mitral stenosis RMBTS = right modified Blalock-Taussig shunt

	References

Top Abstract Introduction Methods Anatomic Findings Results Discussion References

 
1. Gillum RF. Epidemiology of congenital heart disease in the United States. Am Heart J. 1994;127:919-927. [Medline] [Order article via Infotrieve]

2. Norwood WI, Lang P, Hansen DD. Physiologic repair of aortic atresia: hypoplastic left heart syndrome. N Engl J Med. 1983;308:23-26. [Medline] [Order article via Infotrieve]

3. Murdison KA, Baffa JM, Farrell PE, Chang AC, Barber G, Norwood WI, Murphy JD. Hypoplastic left heart syndrome: outcome after initial reconstruction and before modified Fontan procedure. Circulation. 1990;82(suppl IV):IV-199-IV-207.

4. Norwood WI. Hypoplastic left heart syndrome. Ann Thorac Surg. 1991;52:688-695. [Abstract]

5. Bailey LL, Nelsen-Cannarella SL, Doroshow RW, Jacobson JG, Mastin RD, Allard MW, Hyde MR, Dangbui RH, Petry EL. Cardiac allotransplantation in newborns as therapy for hypoplastic left heart syndrome. N Engl J Med. 1986;315:949-951. [Medline] [Order article via Infotrieve]

6. Bailey LL, Gundry SR, Razzouk AJ, Wang N, Sciolaro CM, Chiavarelli M. Bless the babies: one hundred fifteen late survivors of heart transplantation during the first year of life. J Thorac Cardiovasc Surg. 1993;105:805-815. [Abstract]

7. Chiavarelli M, Gundry SR, Razzouk AJ, Bailey LL. Cardiac transplantation for infants with hypoplastic left heart syndrome. JAMA. 1993;270:2944-2947. [Abstract/Free Full Text]

8. Stuart AG, Wren C, Sharples PM, Hunter S, Hey EN. Hypoplastic left heart syndrome: more potential transplant recipients than suitable donors. Lancet. 1991;337:957-959. [Medline] [Order article via Infotrieve]

9. Morris CD, Outcalt J, Menashe VD. Hypoplastic left heart syndrome: natural history in a geographically defined population. Pediatrics. 1990;85:977-983.[Abstract/Free Full Text]

10. Jonas RA. Intermediate procedures after first-stage Norwood operation facilitate subsequent repair. Ann Thorac Surg. 1991;52:696-700. [Abstract]

11. Jonas RA, Hansen DD, Cook N, Wessel D. Anatomic subtype and survival after reconstructive operation for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 1994;107:1121-1128. [Abstract/Free Full Text]

12. Iannettoni MD, Bove EL, Mosca RS, Lupinetti FM, Dorostkar PC, Ludomirsky A, Crowley D, Kulik TJ, Rosenthal A. Improving results with first-stage palliation for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 1994;107:934-940. [Abstract/Free Full Text]

13. Meliones JN, Snider AR, Bove EL, Rosenthal A, Rosen DA. Longitudinal results after first-stage palliation for hypoplastic left heart syndrome. Circulation. 1990;82(suppl IV):IV-151-IV-156.

14. Newburger JW, Jonas RA, Wernovsky G, Wypij D, Hickey PR, Kuban KCK, Farrell DM, Holmes GL, Helmers SL, Constantinou J, Carrazana E, Barlow JK, Walsh AZ, Lucius KL, Share JC, Wessel DL, Hanley FL, Mayer JE, Castaneda AR, Ware JH. Perioperative neurologic effects of hypothermic arrest during infant heart surgery. N Engl J Med. 1993;329:1057-1064.[Abstract/Free Full Text]

This article has been cited by other articles:

				J. H. Artrip, D. N. Campbell, D. D. Ivy, M. C. Almodovar, K.-C. Chan, M. B. Mitchell, D. R. Clarke, and F. Lacour-Gayet Birth Weight and Complexity Are Significant Factors for the Management of Hypoplastic Left Heart Syndrome. Ann. Thorac. Surg., October 1, 2006; 82(4): 1252 - 1259. [Abstract] [Full Text] [PDF]

				K. S. Sundareswaran, K. R. Kanter, H. D. Kitajima, R. Krishnankutty, J. F. Sabatier, W. J. Parks, S. Sharma, A. P. Yoganathan, and M. Fogel Impaired power output and cardiac index with hypoplastic left heart syndrome: a magnetic resonance imaging study. Ann. Thorac. Surg., October 1, 2006; 82(4): 1267 - 1277. [Abstract] [Full Text] [PDF]

				L. Groban, N. A. Pailes, C. D. L. Bennett, C. S. Carter, M. C. Chappell, D. W. Kitzman, and W. E. Sonntag Growth Hormone Replacement Attenuates Diastolic Dysfunction and Cardiac Angiotensin II Expression in Senescent Rats J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2006; 61(1): 28 - 35. [Abstract] [Full Text] [PDF]

				B. Asfour, C. Fink, N. Sinzobahamvya, J. Wetter, A. E. Urban, and J. Photiadis Modified Children's II Operation on the Beating Heart Allows Growth Potential Ann. Thorac. Surg., October 1, 2005; 80(4): e14 - e16. [Abstract] [Full Text] [PDF]

				M. Siepe, D. M Ruegg, M.-N. Giraud, J. Python, T. Carrel, and H. T Tevaearai Effect of acute body positional changes on the haemodynamics of rats with and without myocardial infarction Exp Physiol, July 1, 2005; 90(4): 627 - 634. [Abstract] [Full Text] [PDF]

				S. E. Lipshultz, S. A. Vlach, S. R. Lipsitz, S. E. Sallan, M. L. Schwartz, and S. D. Colan Cardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines Pediatrics, June 1, 2005; 115(6): 1613 - 1622. [Abstract] [Full Text] [PDF]

				D. B. McElhinney, S. D. Colan, A. M. Moran, D. Wypij, M. Lin, J. A. Majzoub, E. C. Crawford, J. M. Bartlett, E. A. McGrath, and J. W. Newburger Recombinant Human Growth Hormone Treatment for Dilated Cardiomyopathy in Children Pediatrics, October 1, 2004; 114(4): e452 - e458. [Abstract] [Full Text] [PDF]

				V. Jayasankar, L. T. Bish, T. J. Pirolli, M. F. Berry, J. Burdick, and Y. J. Woo Local myocardial overexpression of growth hormone attenuates postinfarction remodeling and preserves cardiac function Ann. Thorac. Surg., June 1, 2004; 77(6): 2122 - 2129. [Abstract] [Full Text] [PDF]

				H. Jin, G. Fedorowicz, R. Yang, A. Ogasawara, F. Peale, T. Pham, and N. F. Paoni Thyrotropin-Releasing Hormone Is Induced in the Left Ventricle of Rats With Heart Failure and Can Provide Inotropic Support to the Failing Heart Circulation, May 11, 2004; 109(18): 2240 - 2245. [Abstract] [Full Text] [PDF]

				R. M. Ungerleider, I. Shen, T. Yeh Jr, J. Schultz, R. Butler, M. Silberbach, C. Giacomuzzi, E. Heller, L. Studenberg, B. Mejak, et al. Routine mechanical ventricular assist following the Norwood procedure--improved neurologic outcome and excellent hospital survival Ann. Thorac. Surg., January 1, 2004; 77(1): 18 - 22. [Abstract] [Full Text] [PDF]

				R. G. Dean, L. A. Bach, and L. M. Burrell Upregulation of Cardiac Insulin-like Growth Factor-I Receptor by ACE Inhibition After Myocardial Infarction: Potential Role in Remodeling J. Histochem. Cytochem., June 1, 2003; 51(6): 831 - 839. [Abstract] [Full Text] [PDF]

				N. Nagaya, M. Uematsu, M. Kojima, Y. Ikeda, F. Yoshihara, W. Shimizu, H. Hosoda, Y. Hirota, H. Ishida, H. Mori, et al. Chronic Administration of Ghrelin Improves Left Ventricular Dysfunction and Attenuates Development of Cardiac Cachexia in Rats With Heart Failure Circulation, September 18, 2001; 104(12): 1430 - 1435. [Abstract] [Full Text] [PDF]

				M. K. King, D. M. Gay, L. C. Pan, J. H. McElmurray III, J. W. Hendrick, C. Pirie, A. Morrison, C. Ding, R. Mukherjee, and F. G. Spinale Treatment With a Growth Hormone Secretagogue in a Model of Developing Heart Failure : Effects on Ventricular and Myocyte Function Circulation, January 16, 2001; 103(2): 308 - 313. [Abstract] [Full Text] [PDF]

				V. Hraska, M. Nosal, P. Sykora, V. Sojak, M. Sagat, and P. Kunovsky Results of modified Norwood's operation for hypoplastic left heart syndrome Eur. J. Cardiothorac. Surg., August 1, 2000; 18(2): 214 - 219. [Abstract] [Full Text] [PDF]

				P. D. Sehl, J. T. N. Tai, K. J. Hillan, L. A. Brown, A. Goddard, R. Yang, H. Jin, and D. G. Lowe Application of cDNA Microarrays in Determining Molecular Phenotype in Cardiac Growth, Development, and Response to Injury Circulation, April 25, 2000; 101(16): 1990 - 1999. [Abstract] [Full Text] [PDF]

				W. V. Houck, L. C. Pan, S. B. Kribbs, M. J. Clair, G. M. McDaniel, R. S. Krombach, W. M. Merritt, C. Pirie, J. P. Iannini, R. Mukherjee, et al. Effects of Growth Hormone Supplementation on Left Ventricular Morphology and Myocyte Function With the Development of Congestive Heart Failure Circulation, November 9, 1999; 100(19): 2003 - 2009. [Abstract] [Full Text] [PDF]

				T. Ryoke, Y. Gu, L. Mao, M. Hongo, R. G. Clark, K. L. Peterson, and J. Ross Jr Progressive Cardiac Dysfunction and Fibrosis in the Cardiomyopathic Hamster and Effects of Growth Hormone and Angiotensin-Converting Enzyme Inhibition Circulation, October 19, 1999; 100(16): 1734 - 1743. [Abstract] [Full Text] [PDF]

				J. Ross Jr Growth Hormone, Cardiomyocyte Contractile Reserve, and Heart Failure Circulation, January 12, 1999; 99(1): 15 - 17. [Full Text] [PDF]

				S. Genth-Zotz, R. Zotz, S. Geil, T. Voigtlander, J. Meyer, and H. Darius Recombinant Growth Hormone Therapy in Patients With Ischemic Cardiomyopathy : Effects on Hemodynamics, Left Ventricular Function, and Cardiopulmonary Exercise Capacity Circulation, January 12, 1999; 99(1): 18 - 21. [Abstract] [Full Text] [PDF]

				M. Tajima, E. O. Weinberg, J. Bartunek, H. Jin, R. Yang, N. F. Paoni, and B. H. Lorell Treatment With Growth Hormone Enhances Contractile Reserve and Intracellular Calcium Transients in Myocytes From Rats With Postinfarction Heart Failure Circulation, January 12, 1999; 99(1): 127 - 134. [Abstract] [Full Text] [PDF]

				J. J Sistino Foetal bypass: concepts and controversies Perfusion, March 1, 1998; 13(2): 111 - 117. [Abstract] [PDF]

				K. Wong, K. R. Boheler, M. Petrou, and M. H. Yacoub Pharmacological Modulation of Pressure-Overload Cardiac Hypertrophy : Changes in Ventricular Function, Extracellular Matrix, and Gene Expression Circulation, October 7, 1997; 96(7): 2239 - 2246. [Abstract] [Full Text]

				R. L. Duerr, M. D. McKirnan, R. D. Gim, R. G. Clark, K. R. Chien, and J. Ross Jr Cardiovascular Effects of Insulin-Like Growth Factor-1 and Growth Hormone in Chronic Left Ventricular Failure in the Rat Circulation, June 15, 1996; 93(12): 2188 - 2196. [Abstract] [Full Text]

				C. Lu, G. Schwartzbauer, M. A. Sperling, S. U. Devaskar, S. Thamotharan, P. D. Robbins, C. F. McTiernan, J.-L. Liu, J. Jiang, S. J. Frank, et al. Demonstration of Direct Effects of Growth Hormone on Neonatal Cardiomyocytes J. Biol. Chem., June 15, 2001; 276(25): 22892 - 22900. [Abstract] [Full Text] [PDF]

This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Forbess, J. M. Articles by Jonas, R. A. Search for Related Content PubMed Articles by Forbess, J. M. Articles by Jonas, R. A.